tiprankstipranks
Advertisement
Advertisement
Can-Fite BioPharma Posts 2025 Loss but Highlights Long-Term Cancer Survival and Clinical Progress
PremiumCompany AnnouncementsCan-Fite BioPharma Posts 2025 Loss but Highlights Long-Term Cancer Survival and Clinical Progress
1M ago
CANF Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
CANF Upcoming Earnings Report: What to Expect?
1M ago
Can-Fite Secures Israeli Patent to Bolster Namodenoson Anti-Obesity Franchise
Premium
Company Announcements
Can-Fite Secures Israeli Patent to Bolster Namodenoson Anti-Obesity Franchise
2M ago
Can-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study
PremiumThe FlyCan-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study
2M ago
Can-Fite BioPharma Adjourns Special Shareholders’ Meeting to March 10, 2026
Premium
Company Announcements
Can-Fite BioPharma Adjourns Special Shareholders’ Meeting to March 10, 2026
2M ago
Can-Fite Targets Rare Kidney Disease With New Phase 2 Lowe Syndrome Trial
Premium
Company Announcements
Can-Fite Targets Rare Kidney Disease With New Phase 2 Lowe Syndrome Trial
2M ago
Can-Fite Reports Successful Liver Transplant After Compassionate Use of Namodenoson
PremiumCompany AnnouncementsCan-Fite Reports Successful Liver Transplant After Compassionate Use of Namodenoson
3M ago
Can-Fite announces patient with liver cirrhosis treated with Namodenoson
Premium
The Fly
Can-Fite announces patient with liver cirrhosis treated with Namodenoson
3M ago
Can-Fite BioPharma Calls March 3 Special Meeting to Address NYSE Audit Committee Non-Compliance
Premium
Company Announcements
Can-Fite BioPharma Calls March 3 Special Meeting to Address NYSE Audit Committee Non-Compliance
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100